BIOCYTOGEN PHARMACEUTICALS (BEIJING earnings per share and revenue

2315 earnings per share for the last semiannual are -0.14 HKD whereas the estimation was -0.13 HKD which accounts for -8.33% surprise. Company revenue for the same period amounts to 441.05 M HKD despite the estimated figure of 440.74 M HKD. Estimated earnings per share for the next semiannual are 0.01 HKD, and revenue is expected to reach 577.07 M HKD. Also watch annual changes over time to get a bigger picture of 2315 earnings per share and revenue dynamics.